Skip to main content
Premium Trial:

Request an Annual Quote

Millennium Gobbles Up Predictive Medicine, Eyes Pharmacogenomics Future

Premium

C

AMBRIDGE, Mass.--Millennium Pharmaceuticals announced that it will acquire the remaining shares of its Millennium Predictive Medicine subsidiary that it does not already own, making it a wholly owned subsidiary. The company said that the transaction, a stock-for-stock exchange, will align more closely Millennium’s therapeutic and predictive medicine discovery and development efforts.

The predictive medicine company develops what it calls Diagnomic and pharmacogenomic products and services. Diagnomics are molecular diagnostics that describe a patient’s current medical condition and provide prognostic and therapeutic information. Pharmacogenomic tests determine a patient’s response to a specific therapeutic based on their genetic information.

Filed under

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.